Yoon-Jae Kim

Yoon-Jae Kim

Auto-generated profile, based on publicly available information

Yoon-Jae Kim

Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
JKJi Young Kim
Ji Young Kim
TCTae-Min Cho
Tae-Min Cho
JPJung Min Park
Jung Min Park
SPSoeun Park
Soeun Park
MPMinsu Park
Minsu Park
JSJae Hong Seo
Jae Hong Seo
Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling and does not trigger the HSR, in contrast to other inhibitors. In an orthotopic allograft model incorporating breast cancer stem cell-enriched TNBC tumors, SL-145 potently suppressed tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings highlight the potential of SL-145 in suppressing metastatic TNBC independent of the HSR.

7 September 2022 in Biomaterials
Verified
Journal Article
Closed access
JKJi Hyeon Kim
Ji Hyeon Kim
JPJung Min Park
Jung Min Park
EJEunsun Jung
Eunsun Jung
JLJieun Lee
Jieun Lee
JHJiyou Han
Jiyou Han
Jong Seung KimJong Seung Kim
Jong Seung Kim

4 November 2023 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SKSeongjae Kim
Seongjae Kim
JPJung Min Park
Jung Min Park
SPSoeun Park
Soeun Park
EJEunsun Jung
Eunsun Jung
DKDongmi Ko
Dongmi Ko
JSJae Hong Seo
Jae Hong Seo
Background: Triple-negative breast cancer (TNBC) is characterized by aggressive growth and a high propensity for recurrence and metastasis. Simultaneous overexpression of c-MET and EGFR in TNBC is associated with worse clinicopathological features and unfavorable outcomes. Although the development of new c-MET inhibitors and the emergence of 3rd-generation EGFR inhibitors represent promising treatment options, the high costs involved limit the accessibility of these drugs. In the present study, we sought to investigate the therapeutic potential of doxazosin (DOXA), a generic drug for benign prostate hyperplasia, in targeting TNBC. Methods: The effect of DOXA on TNBC cell lines in vitro was evaluated in terms of cell viability, apoptosis, c-MET/EGFR signaling pathway, molecular docking studies and impact on cancer stem cell (CSC)-like properties. An in vivo metastatic model with CSCs was used to evaluate the efficacy of DOXA. Results: DOXA exhibits notable anti-proliferative effects on TNBC cells by inducing apoptosis via caspase activation. Molecular docking studies revealed the direct interaction of DOXA with the tyrosine kinase domains of c-MET and EGFR. Consequently, DOXA disrupts important survival pathways including AKT, MEK/ERK, and JAK/STAT3, while suppressing CSC-like characteristics including CD44high/CD24low subpopulations, aldehyde dehydrogenase 1 (ALDH1) activity and formation of mammospheres. DOXA administration was found to suppress tumor growth, intra- and peri-tumoral angiogenesis and distant metastasis in an orthotopic allograft model with CSC-enriched populations. Furthermore, no toxic effects of DOXA were observed in hepatic or renal function. Conclusions: Our findings highlight the potential of DOXA as a therapeutic option for metastatic TNBC, warranting further investigation.

13 November 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
SPSoeun Park
Soeun Park
YKYoon-Jae Kim
Yoon-Jae Kim
JPJung Min Park
Jung Min Park
MPMinsu Park
Minsu Park
KNKee Dal Nam
Kee Dal Nam
JSJae Hong Seo
Jae Hong Seo
N-terminal HSP90 inhibitors in development have had issues arising from heat shock response (HSR) induction and off-target effects. We sought to investigate the capacity of NCT-58, a rationally-synthesized C-terminal HSP90 inhibitor, to kill trastuzumab-resistant HER2-positive breast cancer stem-like cells. NCT-58 does not induce the HSR due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills the rapidly proliferating bulk tumor cells as well as the breast cancer stem-like population, coinciding with significant reductions in stem/progenitor markers and pluripotent transcription factors. NCT-58 treatment suppressed growth and angiogenesis in a trastuzumab-resistant xenograft model, concomitant with downregulation of ICD-HER2 and HSF-1/HSP70/HSP90. These findings warrant further investigation of NCT-58 to address trastuzumab resistance in heterogeneous HER2-positive cancers.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
MPMinsu Park
Minsu Park
EJEunsun Jung
Eunsun Jung
JPJung Min Park
Jung Min Park
SPSoeun Park
Soeun Park
DKDongmi Ko
Dongmi Ko
JSJae Hong Seo
Jae Hong Seo
Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for HER2-positive breast cancer patients. Despite the progress of several N-terminal HSP90 inhibitors in clinical trials, none have achieved approval for clinical use, primarily due to issues such as induction of the heat shock response (HSR), off-target effects, and unfavorable toxicity profiles. We sought to examine the effects of HVH-2930, a novel C-terminal HSP90 inhibitor, in overcoming trastuzumab resistance.

20 September 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SPSoeun Park
Soeun Park
JPJung Min Park
Jung Min Park
PMPark Minsu
Park Minsu
DKDongmi Ko
Dongmi Ko
SKSeongjae Kim
Seongjae Kim
JSJae Hong Seo
Jae Hong Seo
Background: The emergence of de novo or intrinsic trastuzumab resistance is exceedingly high in breast cancer that is HER2 positive and correlates with an abundant cancer stem cell (CSC)-like population. We sought to examine the capacity of β-escin, an anti-inflammatory drug, to address trastuzumab resistance in HER2-positive breast cancer cells. Methods: The effect of β-escin on trastuzumab-resistant and -sensitive cell lines in vitro was evaluated for apoptosis, expression of HER2 family members, and impact on CSC-like properties. An in vivo model of trastuzumab-resistant JIMT-1 was used to examine the efficacy and toxicity of β-escin. Results: β-escin induced mitochondrial-mediated apoptosis accompanied by reactive oxygen species (ROS) production and increased active p18Bax fragmentation, leading to caspase-3/-7 activation. Attenuation of CSC-related features by β-escin challenge was accompanied by marked reductions in CD44high/CD24low stem-like cells and aldehyde dehydrogenase 1 (ALDH1) activity as well as hindrance of mammosphere formation. β-escin administration also significantly retarded tumor growth and angiogenesis in a trastuzumab-resistant JIMT-1 xenograft model via downregulation of CSC-associated markers and intracellular domain HER2. Importantly, β-escin selectively inhibited malignant cells and was less toxic to normal mammary cells, and no toxic effects were found in liver and kidney function in animals. Conclusions: Taken together, our findings highlight β-escin as a promising candidate for the treatment of trastuzumab-resistant HER2-positive breast cancers.